GLP-1RA PHARMACOKINETICS AND CLINICAL EFFECTS: FOCUS ON CARDIAC, VASCULAR, AND GLOMERULAR STRUCTURES

Area of Science:

• Cardiology
• Nephrology
• Metabolic Diseases
• Pharmacology

Background:

• Glucagon-like peptide-1 receptor agonists (GLP-1RA) are vital in managing cardio-nephro-metabolic conditions.
• Their impact spans cardiac, vascular, and renal systems, explaining cardiovascular outcomes trial results.
• Pharmacokinetic enhancements, such as extended half-life and albumin binding, increase systemic exposure and efficacy.

Purpose of the Study:

• To review current evidence on GLP-1RA pharmacokinetics, pharmacodynamics, and clinical effects.
• Focus on the drug class's impact on the heart, vasculature, and kidneys.
• Integrate findings to understand the determinants of their clinical profile.

Main Methods:

• Comprehensive literature search until March 2026.
• Databases searched include MEDLINE, EMBASE, Google Scholar, Web of Science, and Cochrane.
• Review integrates pharmacokinetic, pharmacodynamic, and clinical data.

Main Results:

• GLP-1RA show modest chronotropic effects and ischemia-reperfusion protection; direct myocardial effects need further study.
• Vascular benefits are linked to improved endothelial function, reduced oxidative stress, and nitric oxide pathway modulation.
• Renal effects include modulated sodium reabsorption, tubule-glomerular feedback, reduced albuminuria, and slowed decline in kidney function.
• Clinical trials confirm reduced major cardiovascular and renal outcomes.

Conclusions:

• Pharmacokinetics are a critical determinant of GLP-1RA clinical efficacy.
• GLP-1RA demonstrate broad benefits across the cardio-nephro-metabolic spectrum.
• Further research is needed to fully elucidate direct myocardial effects.